Eli Lilly lost over $100 billion in one day.
The reason? Their new obesity pill only helped people lose about 11 percent of their weight, which was far below what the market expected. The stock dropped 14 percent, but here’s the crazy part: it is still trading at over 50 times earnings.
This is not just a bad day. It could be a shift in how investors value the company.
Lilly was priced like every drug would be a blockbuster. But now one of their biggest launches underdelivered. That breaks the story.
Yes, the company is solid. But the stock was priced for perfection, and that just got proven wrong. If investors start revaluing based on actual results, this may not be the bottom yet.
Comments